Work

Molecular profiling of basal cell carcinoma of the prostate: A case report and literature review

Year: 2025

Type: article

Abstract: Prostate basal cell carcinoma (BCC) is a rare pathologic variant with a poorly understood molecular profile. Here, we describe a case of prostate BCC and compare its genetic alterations to cases in the literature. After presenting with hematuria, our patient underwent definitive radical prostatectomy for his localized biopsy-proven BCC. Somatic and germline testing revealed mutations in PIK3R1, KMT2D, and NOTCH1, and MUTYH, NBN, and MSH3, respectively. Upon literature review, we found that prostate BCC mutations disrupt cell growth, epigenetic regulation, and cell fate determination. With no consensus guidelines available, experimental targeted therapies have shown promise for prostate BCC management. • Basal cell carcinoma (BCC) is a rare form of prostate cancer. • Prostate-specific antigen may not be a reliable surveillance method for prostate BCC. • Prostate BCC has genomic alterations that disrupt cell growth and differentiation. • Targeted therapies may treat prostate BCC cases with actionable molecular targets.

Source: Urology Case Reports

DOI: 10.1016/j.eucr.2025.102993

Authors: Luca Bertozzi, Eileen Zhang, Mohadese Behtaj, Olivia Gordon, Yuan James Rao, Michael J. Whalen

Institutions: George Washington University, University of Maryland, College Park, GW Medical Faculty Associates

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,160